E-ISSN 2149-388X | ISSN 2149-0430
 
2023, Vol: 9, Issue: 1
9/1Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Copyright Form
Cover Letter
Title Page

Case Report 


Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?

Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay.

SUPPLEMENTARY FILES :

  • 135-1465934492-adt-1.docx ()

    • Abstract
    Background: Fluid and electrolyte disturbances, especially hyponatremia are common complications after pituitary surgeries. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the leading cause of hyponatremia in hospitals. Fluid restriction is the first step in treatment of SIADH. In rare cases vasopressin receptor inhibitors might be useful for medical treatment.
    Case Presentation: In this paper, we present a case of SIADH after a pituitary surgery with an unpredictable effect of tolvaptan.
    Conclusion: Tolvaptan is the most preferred agent for the treatment of SIADH nowadays. However tolvaptan might cause unpredictable situations in the course of treatment that clinicians must be very careful and in close follow
    up the patient.

    Key words: Hypernatremia, hyponatremia, pituitary surgery, SIADH, tolvaptan


    		 
    ARTICLE TOOLS
    Abstract
    PDF Fulltext
    How to cite this articleHow to cite this article
    Citation Tools
    Related Records
     Articles by Suleyman Karakose
    Articles by Ayse Zeynep Bal
    Articles by Selman Unverdi
    Articles by Murat Duranay
    on Google
    on Google Scholar


    How to Cite this Article
    Pubmed Style

    Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay. Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. Ulutas Med J. 2016; 2(3): 154-156. doi:10.5455/umj.20160703095035

    Web Style

    Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay. Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. https://www.ulutasmedicaljournal.com/?mno=232578 [Access: March 26, 2023]. doi:10.5455/umj.20160703095035

    AMA (American Medical Association) Style

    Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay. Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. Ulutas Med J. 2016; 2(3): 154-156. doi:10.5455/umj.20160703095035


    Vancouver/ICMJE Style

    Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay. Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. Ulutas Med J. (2016), [cited March 26, 2023]; 2(3): 154-156. doi:10.5455/umj.20160703095035


    Harvard Style

    Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay (2016) Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. Ulutas Med J, 2 (3), 154-156. doi:10.5455/umj.20160703095035


    Turabian Style

    Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay. 2016. Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. THE ULUTAS MEDICAL JOURNAL, 2 (3), 154-156. doi:10.5455/umj.20160703095035


    Chicago Style

    Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay. "Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?." THE ULUTAS MEDICAL JOURNAL 2 (2016), 154-156. doi:10.5455/umj.20160703095035


    MLA (The Modern Language Association) Style

    Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay. "Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?." THE ULUTAS MEDICAL JOURNAL 2.3 (2016), 154-156. Print. doi:10.5455/umj.20160703095035


    APA (American Psychological Association) Style

    Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay (2016) Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. THE ULUTAS MEDICAL JOURNAL, 2 (3), 154-156. doi:10.5455/umj.20160703095035


    Author LoginReviewer LoginAbout PublisherEditorial PoliciesPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information
    Copyright © 2023 THE ULUTAS MEDICAL JOURNAL All Rights Reserved. Subject to change without notice from or liability to THE ULUTAS MEDICAL JOURNAL.
    For best results, please use Internet Explorer or Google Chrome

    Contact Information


    Journal Owner
    HAYRİYE ZEHRA ULUTAŞ
    Phone    : +90 (532) 165 96 39​
    E-mail: zehrakenanoglu@hotmail.com​
    Address: Alaattin Mah. 30. Ada sok. D11 Blok
    No:4 Gungor Uydukent Sitesi  Antakya/HATAY

    Editor-In-Chief
    KEMAL TURKER ULUTAS, MD, Assc. Prof.
    Phone    : + 90 (555) 491 35 59​
    E-mail: drkemalturker@gmail.com
    Address: Alaattin Mah. 30. Ada sok. D11 Blok
    No:4 Gungor Uydukent Sitesi  Antakya/HATAY

    Publisher Information
    SCOPEMED Publishing Co. - TURKEY​
    E-mail: scopemed@scopemed.org
    Web: https://www.scopemed.com/

     

    We welcome your submissions, suggestions, comments, or questions. To reach us, please use one of the methods provided on this page or Email us at ulutasmedicaljournal@gmail.com​

    We will respond within 48 to 72 hours.